Identification of Clinical Phenotypes and Related Survival in Patients with Large HCCs.
HCC
PVT
albumin
large
multifocality
phenotypes
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
03 Feb 2021
03 Feb 2021
Historique:
received:
09
12
2020
revised:
16
01
2021
accepted:
27
01
2021
entrez:
6
2
2021
pubmed:
7
2
2021
medline:
7
2
2021
Statut:
epublish
Résumé
Hepatocellular carcinoma (HCC) factors, especially maximum tumor diameter (MTD), tumor multifocality, portal vein thrombosis (PVT), and serum alpha-fetoprotein (AFP), influence survival. To examine patterns of tumor factors in large HCC patients. A database of large HCC patients was examined. A multiple Cox proportional hazard model on death identified low serum albumin levels and the presence of PVT and multifocality, with each having a hazard ratio ≥2.0. All combinations of these three parameters were examined in relation to survival. Using univariate Cox analysis, the combination of albumin >3.5 g/dL and the absence of both PVT and multifocality had the best survival rate, while all combinations that included the presence of PVT had poor survival and hazard ratios. We identified four clinical phenotypes, each with a distinct median survival: patients with or without PVT or multifocality plus serum albumin ≥3.5 (g/dL), with each subgroup displaying high (≥100 IU/mL) or low (<100 IU/mL) blood AFP levels. Across a range of MTDs, we identified only two significant trends, blood AFP and platelets. Patients with large HCCs have distinct phenotypes and survival, as identified by the combination of PVT, multifocality, and blood albumin levels.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatocellular carcinoma (HCC) factors, especially maximum tumor diameter (MTD), tumor multifocality, portal vein thrombosis (PVT), and serum alpha-fetoprotein (AFP), influence survival.
AIM
OBJECTIVE
To examine patterns of tumor factors in large HCC patients.
METHODS
METHODS
A database of large HCC patients was examined.
RESULTS
RESULTS
A multiple Cox proportional hazard model on death identified low serum albumin levels and the presence of PVT and multifocality, with each having a hazard ratio ≥2.0. All combinations of these three parameters were examined in relation to survival. Using univariate Cox analysis, the combination of albumin >3.5 g/dL and the absence of both PVT and multifocality had the best survival rate, while all combinations that included the presence of PVT had poor survival and hazard ratios. We identified four clinical phenotypes, each with a distinct median survival: patients with or without PVT or multifocality plus serum albumin ≥3.5 (g/dL), with each subgroup displaying high (≥100 IU/mL) or low (<100 IU/mL) blood AFP levels. Across a range of MTDs, we identified only two significant trends, blood AFP and platelets.
CONCLUSIONS
CONCLUSIONS
Patients with large HCCs have distinct phenotypes and survival, as identified by the combination of PVT, multifocality, and blood albumin levels.
Identifiants
pubmed: 33546234
pii: cancers13040592
doi: 10.3390/cancers13040592
pmc: PMC7913341
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Hepatology. 2018 Jul;68(1):103-112
pubmed: 29281854
Tumour Biol. 2014 May;35(5):4095-9
pubmed: 24425104
BMC Cancer. 2014 Jan 27;14:43
pubmed: 24468103
Cell Death Dis. 2018 Oct 9;9(10):1027
pubmed: 30301886
Cancers (Basel). 2019 Oct 15;11(10):
pubmed: 31618961
Int J Cancer. 2011 Feb 1;128(3):524-32
pubmed: 20473866
Oncotarget. 2016 Nov 15;7(46):75749-75762
pubmed: 27716619
J Gastroenterol. 2010 Feb;45(2):146-52
pubmed: 19997856
Oncology. 2013;85(3):153-9
pubmed: 23988857
Srp Arh Celok Lek. 2015 Jan-Feb;143(1-2):100-4
pubmed: 25845261
Cancers (Basel). 2019 Jul 20;11(7):
pubmed: 31330817
Semin Oncol. 2014 Jun;41(3):406-414
pubmed: 25023357
J Cell Mol Med. 2016 Mar;20(3):549-58
pubmed: 26756858
Cell Death Dis. 2020 Oct 2;11(10):822
pubmed: 33009373
J Gastrointest Cancer. 2020 Dec;51(4):1215-1219
pubmed: 33006073
Int J Biol Markers. 2014 Sep 30;29(3):e215-23
pubmed: 24526315
Clin Exp Immunol. 2011 Aug;165(2):211-9
pubmed: 21592114
J Hepatol. 2012 Aug;57(2):322-9
pubmed: 22521346
Int J Oncol. 2011 Jul;39(1):245-53
pubmed: 21491085
Hepatology. 2016 Dec;64(6):2077-2088
pubmed: 27178646
Proc Natl Acad Sci U S A. 2012 Aug 7;109(32):E2165-72
pubmed: 22753481
World J Surg. 2014 Nov;38(11):2910-8
pubmed: 25099682
Neoplasma. 2014;61(2):218-24
pubmed: 24299318
Tumori. 1987 Oct 31;73(5):507-12
pubmed: 2446409
Semin Oncol. 2014 Jun;41(3):415-21
pubmed: 25023358
Tumour Biol. 2016 Aug;37(8):10085-96
pubmed: 26820129
Cancer Immunol Res. 2019 Jun;7(6):1001-1012
pubmed: 30988028
Int J Cancer. 1998 Feb 9;75(4):596-9
pubmed: 9466662
Eur J Gastroenterol Hepatol. 2014 Jan;26(1):101-8
pubmed: 23863262
Cancer. 2003 Feb 15;97(4):1042-50
pubmed: 12569604
Hepatology. 2018 Aug;68(2):574-589
pubmed: 29443377
Liver Cancer. 2018 Oct;7(4):335-358
pubmed: 30488023
Liver Transpl. 2005 Sep;11(9):1086-92
pubmed: 16123959
Ann Surg. 2009 Jan;249(1):118-23
pubmed: 19106686
Ann Surg. 1993 Apr;217(4):375-84
pubmed: 8385442
Hepatology. 2018 May;67(5):1784-1796
pubmed: 29159910
J Cell Mol Med. 2020 Dec;24(23):13804-13812
pubmed: 33090723